NOVELION THERAPEUTICS INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net loss and comprehensive loss
Depreciation
Cash used in operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of intangible assets
Stock-based compensation
Non-cash interest expense
Provision for inventory excess and obsolescence
Fair value change in contingent consideration
Unrealized foreign exchange (gain) loss
Fair value loss on investment
Unrealized foreign exchange loss (gain)
Amortization of debt issuance costs and debt discount
Deferred income taxes
Impairment of long-lived assets
Recovery on assets held for sale
Gain on sale of discontinued operations (Note 12)
Gain on sale of long-lived assets
Other non-cash operating activities
Loss on extinguishment of debt
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued liabilities
Accrued and other liabilities
Accrued restructuring
Income taxes receivable/payable

Net cash used in operating activities
Cash used in investing activities
Purchase of property and equipment
Proceeds from mortgage receivable
Other
Proceeds from contingent consideration (Notes 16)
Cash acquired in Merger
Loan receivable
Net proceeds from sale of long-lived assets
Net proceeds from sale of discontinued operations (Note 12)
Net cash used in investing activities

Cash provided by financing activities
Common shares repurchased, including fees
Net proceeds from loan facilities
Issuance of common shares
Cash provided by (used in) financing activities
Cash distribution to common shareholders
Settlement of Backstop Agreement
Aralez investment
Repayment of Shareholder Term Loans
Payment of debt issuance costs
Net cash provided by financing activities
Exchange rate effect on cash
Net decrease in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period

Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for taxes, net
Shares issued in the acquisition (Note 5)
Convertible notes of Aegerion, at fair value (Note 10)
Non-cash investing activities
Purchases of property and equipment included in accounts payable
Non-cash financing activities
Refinance from Roll Up Loans
Retirement of Convertible Notes

Comments